posit tripl top-lin data choic regimen nda delay trial
matur expect modest strength share announc
posit phase data tripl combo het-min cystic
fibrosi cf patient howev updat nda file guidanc modest
neg surpris prior guidanc submiss given previous
announc phase data see thought tripl phase data
think tripl combo high probabl approv us launch
earli like meaning competitor threat
expect vertex expand domin posit het-min popul
ultim treat patient elig cftr modul play
meaning upon launch maintain overweight rate
pt lower outlook tripl sale
pathway market clear potenti approv decis wait
trial matur timelin delay one quarter anticip rapid review
potenti approv late think fda consid strength
data unmet need het-min safeti symdeko backbon look favor
short review though new leadership fda less certain reduc
tripl revenu estim vs con prior po
combo data highlight studi random double-blind placebo
control trial figur het-min patient mean absolut
improv vs pbo homozyg patient
benefit symdeko figur well toler
model updat forecast revenu vs
respect revis non-gaap earn estim
respect
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight anticip near-term growth
kalydeco follow fda decis includ
residu function mutat bolster approv
symdeko earlier overal top-lin growth
larg depend upon develop success
tripl combin phase data posit
submiss plan
faster expect uptak orkambi ou
favor price persist complianc trend
continu expans kalydeco new cf
popul robust uptak symdeko global
rapid develop tripl combin
stagnat ou orkambi neg
discuss regul delay launch
reduc price development delay stumbl
tripl combo rapid develop emerg
compet product approach gene-
tripl combin phase phase data
agentgenotypeabsolut sweat cl- mmol/l cfq-r point ae sae studi discontin mean absolut within mg tez/ ivaphas mg tez/ ivaphas mg tez/ ivaphas mg tez/ ivaphas mg tez iva tripl combotripl treatmenton open label extens barclay
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
